FINWIRES · TerminalLIVE
FINWIRES

Racura Oncology Receives Clearance to Advance Dose Level in Phase One Cardioprotection, Anticancer Synergy Trial

By

Racura Oncology (ASX:RAC) received clearance from the Safety Review Committee to advance the RC220 dose in the first-phase Cardioprotection and Anticancer Synergy trial to the next designated dose level of 80 milligrams per square meter, according to a Friday filing with the Australian bourse.

RC220 is the company's formulation of the anticancer agent (E,E)-bisantrene.

The approval comes following confirmation that the drug showed an acceptable safety profile, with no dose-limiting toxicities or safety concerns noted during the observation period for the first three group one patients dosed at 40 milligrams per square meter, the filing said.

What else is happening in Asia?